SMS alerts can make the difference between a profitable trade and a missed opportunity.
 Text “MOMO” to 555888 to receive our instant, reliable and free SMS alerts.

Traders and Investors,

If you like trading the chart, good risk vs reward set ups, and up and coming biotech's targeting an under-served, multi-billion dollar industry, ZENO is the ticker to get on your screen right away.

ZENO closed at $0.24 with a six month low of $0.20 and a six month high of $0.78. 

It has tested and found support at just above $0.20 on multiple occasions over the past few months. The first time it bounced to $0.40 for 80%+ gains in a couple days, and the second time it ran to around $0.35 for 60% gains in a few days.

We are back to just above $0.20 now, and we think another major bounce could be on the cards.

This appears to be a very solid risk / reward trade setup, with just a few pennies downside (assuming you honor a stop loss at or just below $0.20), and potentially $0.10-20 upside (based on recent highs of $0.35 and technical resistance at $0.40).

Any way you slice it, ZENO could make for a nice trade at these levels.

Zenosense, Inc. (ZENO) participates in the development of transformational medical diagnostic technologies: hand-held devices used at the Point of Care replacing slow and expensive laboratory testing.

Their core focus through a joint venture in MIDS Medical (http://midsmed.com/) is the development and commercialization of MIDS Cardiac™. A hand held device being developed for use at the Point of Care for the rapid testing of cardiac markers delivering results equal or superior to laboratory gold standard accuracy within minutes. A device which could revolutionize the diagnosis and management of suspected Acute Myocardial Infarction (AMI).

Per their website, ZENO's team of professionals has world class expertise and technical know-how of the application of highly specific nano magnetic particle technology to medical testing.  This knowledge, alongside their commercial experience of the Point of Care market, puts MIDS Medical in an excellent position to commercialise MIDS Cardiac™ and become the leading innovator in this field.

Cardiovascular disease is the leading cause of death in the Western World

Accounting for more than 17 million deaths p.a. In Europe and the US alone approximately 15-20 million patients a year visit an Emergency Department (ED) reporting chest pain which must be investigated as possibly caused by a cardiac event.

And billions of dollars per year is spent on unnecessary admissions in the US alone.

Acute Myocardial Infarction (heart attack, Acute Myocardial Infraction “AMI”) affects all of us at some point in our lives, directly or indirectly, Rapid diagnosis is key; treatment in the first “Golden Hour” being crucial to survival. Equally, early “rule out” of AMI as the cause of chest pain can save healthcare providers $billions.

ZENO has a solution that could change the equation, and revolutionize the diagnosis of potential and actual heart attack victims. 

Led by renowned physician, Dr. Nasser Dejennati, ZENO is using patented technology to develop a hand-held device for quick analysis of heart attack victims that saves emergency medical professionals precious time in evaluating their patients condition, and a better opportunity to save lives.

Their groundbreaking device, called MIDS Cardiac, gives medical providers the same benefits as lengthy laboratory testing only in a hand-held device, with results available in minutes.

Massive Market Opportunity

The global market for cardiac biomarker diagnostic tests is projected to reach $7.2 billion by 2018, of which $1.16 billion is expected to be served by Point of Care devices.

The Point of Care market is in its infancy; existing Point of Care hand held devices are not accurate or reliable enough to definitively exclude AMI.

ZENO's ultimate goal is to match or exceed current “Gold Standard” high-sensitivity cardiac assays, currently carried out on relatively slow, hugely expensive laboratory analyzers. One multinational diagnostic company claiming the highest levels of accuracy on the market for a  Point of Care cardiac marker device in reality achieves a mere 65% sensitivity (correctly identifying the condition).

You can learn more about ZENO on their website http://www.zenosense.com/

ZENO is a hot biotech with real growth potential operating in a massively growing multi-billion dollar market.

With a small market cap, and a chart that is showing strong multi-month support, we think ZENO could make for a nice trade idea, potentially over multiple days, even weeks.

Do your research on ZENO now and be ready to trade at market open.
 

 

 

Remember our key trading rules when trading. Capital preservation is key. Keep your stops tight, and if things don't go your way, cut your losses and look for another opportunity.